Search - tctmd.com

Displaying 41 - 60 of 130

Sort: Relevancy | Date

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Daily News

Statins Underprescribed in PAD Before and After Interventions

L.A. McKeown

December 03, 2021

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

L.A. McKeown

October 06, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

L.A. McKeown

August 05, 2021

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

Critical Limb Ischemia During COVID: Lessons for Care and Clinical Trials

L.A. McKeown

April 26, 2021

News Daily News

LITE: High- Beats Low-Intensity Exercise at Home for Improving PAD

L.A. McKeown

April 09, 2021

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Daily News

No Paclitaxel Death Signal in VA Data Out to 3 Years

L.A. McKeown

February 11, 2021

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Conference News AHA 2020

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

L.A. McKeown

November 13, 2020

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

Advertisement

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

February 2022 News Roundup

Statins Underprescribed in PAD Before and After Interventions

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

PAD Continues to Elude Clinicians, Despite Gains: AHA

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

Critical Limb Ischemia During COVID: Lessons for Care and Clinical Trials

LITE: High- Beats Low-Intensity Exercise at Home for Improving PAD

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

No Paclitaxel Death Signal in VA Data Out to 3 Years

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content